Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | AMY2A | P04746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23704408 | 1.00 | LGALS8 (0.31) | LGALS8L3MBTL1MAPTAMY2A | |
| SCHEMBL20534691 | 1.00 | LGALS8 (0.31) | LGALS8L3MBTL1MAPTAMY2A | |
| SCHEMBL23352090 | 0.90 | AMY2A (0.32) | LGALS8L3MBTL1AMY2A | |
| SCHEMBL13728774 | 0.89 | LGALS8 (0.39) | LGALS8AMY2A | |
| SCHEMBL21517909 | 0.89 | LGALS8 (0.39) | LGALS8AMY2A | |
| SCHEMBL16687789 | 0.89 | LGALS8 (0.39) | LGALS8AMY2A | |
| SCHEMBL19317375 | 0.85 | — | — | |
| SCHEMBL17540865 | 0.81 | AMY2A (0.41) | LGALS8L3MBTL1AMY2A | |
| SCHEMBL931603 | 0.81 | LGALS8 (0.32) | LGALS8 | |
| SCHEMBL16518072 | 0.81 | LGALS8 (0.32) | LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139164-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-02 | — | — | US | disclosed |
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| US-20240131012-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-25 | — | — | US | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| EP-4069223-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | Anakuria Therapeutics, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20210186935-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | US | disclosed |
| WO-2021113665-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| EP-3426246-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | National Health Research Institutes (TW) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | LGALS8 4472/4885L3MBTL1 4651/4885MAPT 1648/4885 |
| US-20210186935-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | LGALS8 2683/4885L3MBTL1 1577/4885MAPT 2231/4885 |
| US-20240139164-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | LGALS8 2683/4885L3MBTL1 1577/4885MAPT 2231/4885 |
| US-20240131012-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | LGALS8 2683/4885L3MBTL1 1577/4885MAPT 2231/4885 |
| US-11819476-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | LGALS8 4466/4885L3MBTL1 2979/4885MAPT 2773/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | LGALS8 4472/4885L3MBTL1 4651/4885MAPT 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.